The authorized shares were already in place with the shell company that Medify merged with to go public. In other words, this was not done by Medify's management...rather, they inherited the authorized share amount.
Most companies authorize many more shares than they intend to actually issue. With the potential revenue that Medify is capable of developing over the next few months, I highly doubt that they will dilute what I consider to be an already large O/S share amount...they would only be hurting themselves with such dilution. Typically only a starving company will continue to dilute as they need money. That does not appear to be the case with Medify.